Platelet Reactivity over Time and Clinical Outcomes in Medically Managed ACS

In a substudy of TRILOGY acute coronary syndromes, the VerifyNow device detected no useful associations.

In the TRILOGY ACS trial, no association was found between platelet reactivity and clinical outcomes in patients with acute coronary syndromes without ST-segment elevation initially treated medically (JW Cardiol Aug 26 2012). In a prespecified substudy, 27.5% of the 9326 TRILOGY ACS participants randomized to prasugrel (age <75 and weight ≥60 kg, 10 mg/day; age ≥75 or weight <60 kg, 5 mg/day) or clopidogrel (75 mg/day) underwent platelet-reactivity testing at baseline, 2 hours after randomization, and at 1, 3, 6, 12, 18, 24, and 30 months of study drug treatment. Platelet inhibition was measured in P2Y₁₂ reaction units (PRUs) with the VerifyNow device.

At 30 days, median PRU values were significantly lower in the prasugrel group than in the …

Reviewing Author

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)